Market News
Stocks to watch today: Nvidia sinks as its board weighs ousting Jensen Huang, and Lilly hits a record on China's weight-loss pill approval
Nasdaq 100 futures are down about 0.9% after reports that Nvidia's board met to discuss removing CEO Jensen Huang sent the stock down about 7.5% premarket. AMD and Broadcom gain on the rotation, Lilly hits a record after China approves its weight-loss pill, and jobless claims land at 8:30 ET.
Thursday 12 November opens with Wednesday's rebound already unwound. The S&P 500 rose 1.31% to 7,619.38 on Wednesday, the Nasdaq Composite gained 1.60% to 25,466.19 and the Dow added 0.49% to 52,486.49, as CoreWeave's earnings beat lifted the whole AI complex. This morning the mood has flipped. As of about 07:08 ET, Nasdaq 100 futures were down 0.93% at 28,209, or 264 points lower; S&P 500 futures were down 0.42% at 7,609, or 32 points lower; Dow futures were little changed at 52,597, up 0.04%; and Russell 2000 futures were down 0.13% at 2,850. One stock is doing almost all of the damage.
Nvidia (NVDA): the board, not the business, is the story
Nvidia was down about 7.5% premarket to around $160.69 as of 07:18 ET, after closing Wednesday at $173.73, up 2.92% on the day. The shares had already fallen 8.61% in after-hours trading on Wednesday to $158.78. The trigger is governance, not demand. The Wall Street Journal reported on Wednesday that Nvidia's board is preparing to remove chief executive Jensen Huang, and Reuters reported that the board met late on Wednesday to discuss his future. Bloomberg reported that the board is working with an external firm to search for potential successors and is considering appointing an interim chief executive. As of this morning, no decision has been announced, and Huang remains chief executive.
The background: on 8 November the board announced an independent investigation and hired the law firm Wachtell, Lipton, Rosen & Katz to conduct it, after reports that Huang had been targeted by a foreign intelligence operation. The New York Times has since reported a second extramarital affair, with Kimberly Powell, Nvidia's vice president of healthcare. Reuters noted that if the premarket losses held, Nvidia would have lost about $600 billion in market value since the board announced its investigation.
Why it matters: Nvidia is the largest single weight in the AI trade, and its third-quarter results are due on Tuesday 17 November, with an earnings call at 5 p.m. ET. The Nasdaq 100 is now about 9% below its October peak, and its forward price-to-earnings ratio has dropped to around 17 times, below the S&P 500's roughly 18 times. Watch for any statement from the board before the open, whether the shares can hold above $160, and whether the selling spreads beyond Nvidia into the rest of the chip complex.
The chip complex: rotation into AMD and Broadcom, CoreWeave gives back
Not every chip stock is falling. AMD was up 2.50% premarket to $566.72 as of 07:18 ET, and Broadcom was up more than 2%, as investors bet that customers may diversify their chip purchases if Nvidia's leadership is in doubt. The rest of the sector is under pressure: Intel, Marvell and Micron were down 2.6% to 3.4% premarket, with SK Hynix down nearly 4%, SanDisk and Micron down more than 3%, and Coherent down more than 4%.
CoreWeave was down about 4.9% premarket as of 05:32 ET, giving back part of Wednesday's 24.71% surge to $60.77 — its best day since April 2025. The pullback comes despite the numbers that drove the rally: third-quarter revenue of $3.66 billion, up 168% year over year and ahead of the roughly $3.55 billion analysts expected, and raised full-year guidance of $13.0 billion to $13.3 billion.
Why it matters: Wednesday showed the AI trade can still rally hard on real demand. Thursday shows how fast that rally reverses when the story shifts from earnings to governance. Watch whether AMD and Broadcom hold their gains through the session — a rotation that sticks would say investors are re-pricing the AI supply chain, not just selling Nvidia.
Eli Lilly (LLY): a record high on China's weight-loss pill approval
Eli Lilly was up 2.87% premarket to $1,479.07 as of 07:18 ET, a record high. China has approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill — ahead of Novo Nordisk, whose oral Wegovy is still awaiting a Chinese decision. J.P. Morgan forecasts that China's GLP-1 weight-management sales could reach 30 billion yuan, about $4.5 billion, within five to seven years. Lilly's shares have gained nearly 38% so far in 2026, compared with an 18.6% fall for Novo Nordisk, and Foundayo recorded $184 million in sales in the third quarter.
Why it matters: this is the morning's clearest company-specific win, and it is coming from healthcare, not technology — a useful counterweight on a day when tech is dragging the indices lower. Watch whether the gain holds into the open and whether Novo Nordisk, down with the broader market, steadies on the news that its rival now has a head start in China.
What else to watch today
Strategy (MSTR) was down 5.65% premarket to $115.44 as cryptocurrencies fell 2.4% to 3% alongside the flight to safety. Treasuries are rallying across the curve, and gold futures were down 1.17% at $3,953.50 while the dollar hit a 19-month high.
On the data calendar, initial jobless claims land at 8:30 ET, and the producer price index follows tomorrow. Cleveland Fed President Hammack speaks today, and Fed Governor Barr speaks on artificial intelligence at 11:00 ET. Deutsche Bank now expects the Federal Reserve to raise rates at each of its next three meetings, with no pause in January, and markets are fully pricing in a December increase. On earnings, Nebius reports before the open, while Cisco and Applied Materials report after the close, with AI orders in focus.
Overnight, Asia was mostly lower — the Hang Seng fell 1.2%, the Nikkei 0.7%, South Korea's Kospi 0.6% and Taiwan's Taiex 2.6% — while Europe opened higher, with Germany's DAX up 0.82% and France's CAC 40 up 0.73%. Oil is softer: West Texas Intermediate was down 0.81% at $85.83 a barrel and Brent down 0.71% at $92.10, and the euro has fallen below 1.11 against the dollar, its lowest since May 2025.
The overall picture
Wednesday was an earnings story: CoreWeave's numbers revived the AI trade and pulled the S&P 500 to within 2.6% of its record close of 7,819.04, set on 6 October. Thursday is a governance story, and it is a bigger one for the index — Nvidia alone is dragging the Nasdaq lower, and the question hanging over the open is not whether AI demand is real but who will be running the company that supplies it. With the Fed now expected to raise rates again in December, the market has two headwinds at once: dearer money and a leadership crisis at its most important stock. The first hour will show whether buyers step in below $160 in Nvidia, or whether the rotation into AMD, Broadcom and Lilly becomes the day's real trade.
For education only. Not financial advice.
Sources
- Regards of Wall Street: Stock Market Futures Today — S&P 500 Futures Down 0.42% Before the Open, Nov 12
- The Rest Of It: All Eyes on Nvidia's Board, and Nasdaq Futures Slip
- XTB: Morning Wrap — Nvidia sell-off weighs on indices
- TradingKey: Nvidia Falls Over 7% Premarket, AMD and Broadcom Buck Trend to Gain Over 2%
- FinanceFeeds: AMD Stock Up 4.3% as WSJ Says Nvidia Board May Oust Huang
- Stock Market Watch: Premarket Movers — Top Gainers, Losers & Most Active Stocks
- Blockonomi: Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill
- Stocktwits: Eli Lilly's Orforglipron Wins Big In China
- Market Briefer: The Global Close — November 11, 2026
- Mitrade: Nasdaq Extends Gains by 1.6%, SOX Surges Over 5%
- Longbridge: US Stock Preview — Mixed Performance in Major Index Futures
- Frenzy Capital: Stock Market Analysis for Thursday, November 12, 2026